title: Pharmacokinetic evaluation of fosaprepitant dimeglumine.
abstract: BACKGROUND
  Chemotherapy induced nausea and vomiting (CINV) is a common complication in the treatment of patients with cancer. The introduction of the first in class neurokinin-1 receptor antagonist aprepitant provided additive control on CINV in combination to existing antiemetics. Due to formulation issues, aprepitant is only available for oral administration. Fosaprepitant, a prodrug of aprepitant, was introduced to the market in 2008 as an intravenous bioequivalent to aprepitant.
  
  
  METHODS
  This review examines the chemical development of fosaprepitant, its pharmacokinetic properties, approved uses and potential applications.
  
  
  RESULTS
  The reader will get up-to-date information on the pharmacology and clinical uses of fosaprepitant. Clinical studies have demonstrated pharmacokinetic bioequivalence of aprepitant 125 mg to fosaprepitant 115 mg, as well as comparable efficacy in prevention of acute and delayed emesis following the first day of chemotherapy regimens.
  
  
  CONCLUSIONS
  Fosaprepitant is an intravenous prodrug of aprepitant that offers a new alternative to patients with CINV. Currently, fosaprepitant can substitute oral aprepitant in day 1 of a 3-day regimen. Current studies show that a single-day fosaprepitant regimen is also bioequivalent to the 3-day aprepitant regimen; this could significantly simplify the care for CINV patients in the future.
authors.affiliation: Thomas Jefferson University, Department of Pharmacology and Experimental Therapeutics, 1170 Main Building, 132 S. 10th St., Philadelphia, PA 19107, USA.
authors.forename: Francheska
authors.initials: F
authors.lastname: Colon-Gonzalez
authors.forename: Walter K
authors.initials: WK
authors.lastname: Kraft
mesh_terms: D000818:Animals; D000932:Antiemetics / Q000493:pharmacokinetics* / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D000077608:Aprepitant; D006801:Humans; D009025:Morpholines / Q000493:pharmacokinetics* / Q000494:pharmacology; D009325:Nausea / Q000139:chemically induced / Q000517:prevention & control; D009369:Neoplasms / Q000188:drug therapy; D064729:Neurokinin-1 Receptor Antagonists; D011355:Prodrugs; D013810:Therapeutic Equivalency; D014839:Vomiting / Q000139:chemically induced / Q000517:prevention & control
chemical_list: D000932:Antiemetics; D000970:Antineoplastic Agents; D009025:Morpholines; D064729:Neurokinin-1 Receptor Antagonists; D011355:Prodrugs; D000077608:Aprepitant; C579707:fosaprepitant
references.citation: Oncologist. 2007 Sep;12(9):1143-50
references.pmid: 17914084
references.citation: Eur J Clin Pharmacol. 2005 Jul;61(5-6):341-6
references.pmid: 15983826
references.citation: J Clin Oncol. 2003 Nov 15;21(22):4112-9
references.pmid: 14559886
references.citation: Invest New Drugs. 2010 Apr;28(2):187-93
references.pmid: 19148578
references.citation: Adv Drug Deliv Rev. 2007 Jul 30;59(7):631-44
references.pmid: 17601629
references.citation: Cancer. 2003 Jun 15;97(12):3090-8
references.pmid: 12784346
references.citation: Anesthesiol Clin. 2010 Jun;28(2):225-49
references.pmid: 20488392
references.citation: Cancer. 2002 Jun 1;94(11):3032-41
references.pmid: 12115394
references.citation: Value Health. 2007 Jan-Feb;10(1):23-31
references.pmid: 17261113
references.citation: J Pain Palliat Care Pharmacother. 2005;19(3):31-9
references.pmid: 16219609
references.citation: J Clin Psychiatry. 2002;63 Suppl 11:18-24
references.pmid: 12562139
references.citation: Ann Oncol. 2006 Jan;17(1):20-8
references.pmid: 16314401
references.citation: Int J Nanomedicine. 2008;3(3):295-309
references.pmid: 18990939
references.citation: J Clin Oncol. 2011 Apr 10;29(11):1495-501
references.pmid: 21383291
references.citation: Ann Oncol. 2009 May;20 Suppl 4:156-8
references.pmid: 19454442
references.citation: Eur J Pharmacol. 1993 Nov 30;250(1):R5-6
references.pmid: 8119305
references.citation: Ann Oncol. 2010 May;21 Suppl 5:v232-43
references.pmid: 20555089
references.citation: J Med Chem. 2000 Mar 23;43(6):1234-41
references.pmid: 10737756
references.citation: Support Care Cancer. 2006 Apr;14(4):354-60
references.pmid: 16450086
references.citation: J Clin Oncol. 2005 Apr 20;23(12):2822-30
references.pmid: 15837996
references.citation: Eur J Cancer. 2001 May;37(7):835-42
references.pmid: 11313170
references.citation: Ann Oncol. 2006 Jun;17(6):1000-6
references.pmid: 16524979
references.citation: Anesth Analg. 2009 Aug;109(2):418-25
references.pmid: 19608812
references.citation: J Clin Oncol. 2006 Jun 20;24(18):2932-47
references.pmid: 16717289
references.citation: Drugs. 2009;69(13):1853-78
references.pmid: 19719336
references.citation: J Clin Pharmacol. 2006 Mar;46(3):291-300
references.pmid: 16490805
references.citation: Drug Metab Dispos. 1999 Nov;27(11):1367-73
references.pmid: 10534323
references.citation: J Clin Pharmacol. 2007 Jul;47(7):834-40
references.pmid: 17525168